Cost-effectiveness of 3 months of weekly rifapentine and isoniazid compared with other standard treatment regimens for latent tuberculosis infection: a decision analysis study | Zendy

Tan Doan | Zendy; Greg J. Fox | Zendy; Michael T. Meehan | Zendy; Nick Scott | Zendy; Romain Ragonnet | Zendy; Kerri Viney | Zendy; James M. Trauer | Zendy; Emma S. McBryde | Zendy

Open Access

Cost-effectiveness of 3 months of weekly rifapentine and isoniazid compared with other standard treatment regimens for latent tuberculosis infection: a decision analysis study

Author(s) -

Tan Doan,

Greg J. Fox,

Michael T. Meehan,

Nick Scott,

Romain Ragonnet,

Kerri Viney,

James M. Trauer,

Emma S. McBryde

Publication year - 2018

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dky403

Subject(s) - rifapentine , isoniazid , medicine , latent tuberculosis , regimen , rifampicin , tuberculosis , cost effectiveness , cost effectiveness analysis , cohort , surgery , mycobacterium tuberculosis , pathology , risk analysis (engineering)

Latent tuberculosis infection (LTBI) is a critical driver of the global burden of active TB, and therefore LTBI treatment is key for TB elimination. Treatment regimens for LTBI include self-administered daily isoniazid for 6 (6H) or 9 (9H) months, self-administered daily rifampicin plus isoniazid for 3 months (3RH), self-administered daily rifampicin for 4 months (4R) and weekly rifapentine plus isoniazid for 3 months self-administered (3HP-SAT) or administered by a healthcare worker as directly observed therapy (3HP-DOT). Data on the relative cost-effectiveness of these regimens are needed to assist policymakers and clinicians in selecting an LTBI regimen.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research